Caris Life Sciences, Inc.
CAI
$18.24
-$0.24-1.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | 96.97% | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 96.97% | -- | -- | -- | |
| Cost of Revenue | 16.89% | -- | -- | -- | |
| Gross Profit | 199.86% | -- | -- | -- | |
| SG&A Expenses | 21.57% | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 14.57% | -- | -- | -- | |
| Operating Income | 117.55% | -- | -- | -- | |
| Income Before Tax | 75.85% | -- | -- | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 75.85% | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 75.85% | -- | -- | -- | |
| EBIT | 117.55% | -- | -- | -- | |
| EBITDA | 132.53% | -- | -- | -- | |
| EPS Basic | -4.60% | -- | -- | -- | |
| Normalized Basic EPS | 58.18% | -- | -- | -- | |
| EPS Diluted | -4.72% | -- | -- | -- | |
| Normalized Diluted EPS | 57.95% | -- | -- | -- | |
| Average Basic Shares Outstanding | 368.25% | -- | -- | -- | |
| Average Diluted Shares Outstanding | 388.67% | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |